Search

everythinglearnresearchcommunity

for

Search:↓

An 18-year-old shared his 3-month hair regrowth progress using Kirkland 5% topical minoxidil and a dermaroller, achieving a better hairline without finasteride. He plans to switch from liquid to foam minoxidil for easier styling and is cautious about starting finasteride due to potential hormonal effects.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

The user has been using oral finasteride and topical minoxidil for years without success and is seeking alternative treatments. Suggestions include switching to oral minoxidil, adding dutasteride, trying topical treatments, or considering microneedling.

Hair growth caps and helmets using low-level laser therapy (LLLT) show potential for treating androgenetic alopecia, but more research is needed. Users often combine these devices with treatments like minoxidil and finasteride for better results.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

A 24-year-old male has been using 5% minoxidil for five years and recently added 0.025% topical finasteride to his routine. He noticed some improvement in his crown area but is considering stronger treatments like oral finasteride or dutasteride for better results, especially on the temples.

A user experienced no visible improvement in hair loss after 10 months on 0.5mg finasteride and increased the dose to 1mg, noticing a possible shedding phase. They also use topical minoxidil, ketoconazole shampoo, and dermastamping, and are seeking others' experiences with similar treatments.

Avoid home-compounding topical minoxidil due to potential risks and complications. Use proper equipment and techniques to prevent aerosolization and ensure effective dissolution.

A 31-year-old Australian had a successful hair transplant in Turkey for $10,000 AUD, using minoxidil and finasteride to combat hair loss. He now has a full head of hair, increased confidence, and continues using finasteride with occasional minoxidil.

The user has been taking finasteride and biotin for 80 days and is considering starting minoxidil after six months. Opinions vary, with some suggesting starting minoxidil immediately for better results, while others advise patience with finasteride.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

A 27-year-old actor shared his positive experience with two hair transplant surgeries, highlighting the importance of customization and detail for a natural look. He is taking finasteride to prevent future hair loss.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

A dermatologist prescribed 0.5 mg dutasteride and 2.5 mg minoxidil for hair thinning, which is considered a solid regimen for regrowth. Users generally agree that dutasteride is more effective than finasteride and support the dermatologist's decision.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

A 21-year-old male is experiencing crown balding and is using RU58841, topical minoxidil, and plans to add dutasteride and oral minoxidil to his treatment. He seeks advice on increasing his treatment stack despite previous side effects like chest pain.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

The user shares a positive experience with Dutasteride for hair loss, noting increased hair density and minimal side effects after switching from Finasteride. They prefer oral Dutasteride and avoid Minoxidil due to its inconvenience and potential risks.

The user is using minoxidil, finasteride, dutasteride, and clobetasol, along with needling, to combat hair loss. They are considering stopping treatment if no improvement is seen.

Minoxidil and finasteride have not improved the user's hairline after a year. Suggestions include trying dutasteride, microneedling, or considering a hair transplant for better results.

A 26-year-old is considering switching from a regimen of minoxidil, finasteride, and RU58841 to possibly include pyrilutamide due to insufficient results in slowing hair loss. They are seeking advice on whether to add pyrilutamide or replace RU58841 with it, considering cost and effectiveness.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.

The user started shedding hair after beginning testosterone replacement therapy (TRT) despite using dutasteride and minoxidil, and added RU58841 to address the shedding. They reduced their TRT dose and hope RU58841 will stop the shedding quickly.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.